Guidance for the diagnosis, prevention and therapy of osteoporosis in Italy

Clinical Cases in Mineral and Bone Metabolism

Volumn 9, Issue 3, 2012, Pages 170-178

  Cianferotti, Luisella ^a   Brandi, Maria Luisa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

DEXA; Fractures; Guidelines; Male osteoporosis; Risk factors; Secondary osteoporosis

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; CALCIUM; CLODRONIC ACID; DENOSUMAB; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE DERIVATIVE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; BONE DEMINERALIZATION; CALCIUM INTAKE; CORTICOSTEROID INDUCED OSTEOPOROSIS; COST EFFECTIVENESS ANALYSIS; DRESS SYNDROME; DRUG EFFICACY; DRUG SAFETY; ESTROGEN THERAPY; HEALTH ECONOMICS; HUMAN; IDIOPATHIC POSTMENOPAUSAL OSTEOPOROSIS; ITALY; KYPHOPLASTY; MEDICAL SOCIETY; MORPHOMETRICS; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOPOROSIS; PERCUTANEOUS VERTEBROPLASTY; PHYSICAL ACTIVITY; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIMARY HYPERPARATHYROIDISM; PUBLIC HEALTH; RISK ASSESSMENT; SECONDARY OSTEOPOROSIS; TRANSPLANTATION OSTEOPOROSIS; TREATMENT OUTCOME; VERTEBRAL MORPHOMETRY;

EID: 84871886881     PISSN: 17248914     EISSN: 19713266     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Adler RA, Bates DW, Dell RM, et al. Systems-based approaches to osteoporosis and fracture care: policy and research recommendations from the workgroups. Osteoporos Int 2011;22 Suppl 3:495-500.
2. Adami S, Bertoldo F, Brandi ML, et al. Guidelines for the diagnosis, prevention and treatment of osteoporosis. Società Italiana dell'Osteoporosi, del Metabolismo Minerale e delle Malattie dello Scheletro. Reumatismo 2009;61:260-284.
3. Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract 2010;16:1016-1019.
4. Body JJ, Bergmann P, Boonen S, et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 2010;21:1657-1680.
5. Czerwiński E, Badurski J, Lorenc R, Osieleniec J. Guidelines on the Diagnosis of Osteoporosis and Assessment of Fracture Risk in Poland of III Central European Congress on Osteoporosis and Osteoarthritis, XV Congress of the Polish Osteoarthrology Society and Polish Foundation of Osteoporosis. Ortop Traumatol Rehabil 2010;12:194-200.
6. Papaioannou A, Morin S, Cheung AM, et al. Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010;182:1864-1873.
7. Lentle B, Cheung AM, Hanley DA, et al. Scientific Advisory Council of Osteoporosis Canada. Osteoporosis Canada 2010 guidelines for the assessment of fracture risk. Can Assoc Radiol J 2011;62:243-250.
8. Heberlein I, Demary W, Bloching H, et al. Diagnosis and treatment of osteoporosis and rheumatoid arthritis in accordance with German guidelines. Results of a survey of patients, primary care physicians and rheumatologists. Z Rheumatol 2011;70:592-601.
9. Makras P, Vaiopoulos G, Lyritis GP; Greek National Medicine Agency. 2011 guidelines for the diagnosis and treatment of osteoporosis in Greece. J Musculoskelet Neuronal Interact 2012;12:38-42.
10. Briot K, Cortet B, Thomas T, et al. 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 2012;79:304-313.
11. Pérez Edo L, Alonso Ruiz A, Roig Vilaseca D, et al. Spanish Society of Rheumatology. 2011 Up-date of the consensus statement of the Spanish Society of Rheumatology on osteoporosis. Reumatol Clin 2011;7:357-379.
12. Reyes García R, Jódar Gimeno E, García Martín A, et al. Grupo de Metabolismo Mineral de la Sociedad Española de Endocrinología y Nutrición. Clinical practice guidelines for evaluation and treatment of osteoporosis associated to endocrine and nutritional conditions. Bone Metabolism Working Group of the Spanish Society of Endocrinology. Endocrinol Nutr 2012;59:174-196.
13. Li-Yu J, Perez EC, Cañete A, et al. Osteoporosis Society of Philippines Foundation, Inc. (OSPFI); Philippine Orthopedic Association (POA) Clinical Practice Guidelines Task Force Committee on Osteoporosis. Consensus statements on osteoporosis diagnosis, prevention, and management in the Philippines. Int J Rheum Dis 2011;14:223-238.
14. Rabar S, Lau R, O'Flynn N, et al. Guideline Development Group. Risk assessment of fragility fractures: summary of NICE guidance. BMJ 2012 Aug 8;345:e3698.
15. Kanis JA, McCloskey EV, Johansson H, et al. on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2012 Oct 19. [Epub ahead of print].
16. Orimo H, Nakamura T, Hosoi T, et al. Japanese 2011 guidelines for prevention and treatment of osteoporosis-executive summary. Arch Osteoporos 2012.
17. Watts NB, Adler RA, Bilezikian JP et al. Endocrine Society. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97:1802-1822.
18. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010;62:1515-1526.
19. Lekamwasam S, Adachi JD, Agnusdei D, et al. Joint IOF-ECTS GIO Guidelines Working Group. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 2012;23:2257-2276.
20. Pereira RM, Carvalho JF, Paula AP, et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol 2012;52:580-593.
21. Hadji P, Hartenfels M, Kyvernitakis J, et al. Recommendations for antiresorptive therapy in postmenopausal patients with breast cancer: Marburg AIBL Guideline Evaluation Study (MAGES). Breast Cancer Res Treat 2012;133:1089-1096.
22. Rizzoli R, Body JJ, De Censi A, et al. on behalf of the European Society for Clinical and Economical aspects of Osteoporosis and Osteoarthritis (ESCEO). Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int 2012;23:2567-2576.
23. U.S. Preventive Services Task Force. Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med 2011;154:356-364.
24. Powell H, O'Connor K, Greenberg D. Adherence to the U.S. Preventive Services Task Force 2002 osteoporosis screening guidelines in academic primary care settings. J Womens Health (Larchmt) 2012;21:50-53.
25. Dawson-Hughes B, Looker AC, Tosteson AN, et al. The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008. Osteoporos Int 2012 Mar;23(3):811-20.
26. Biver E. Use of bone turnover markers in clinical practice. Curr Opin Endocrinol Diabetes Obes 2012;19:468-473.
27. Dasher LG, Newton CD, Lenchik L. Dual X-ray absorptiometry in today's clinical practice. Radiol Clin North Am 2010;48:541-560.
28. Lang TF. Quantitative computed tomography. Radiol Clin North Am 2010;48:589-600.
29. Guglielmi G, Scalzo G, de Terlizzi F, Peh WC. Quantitative ultrasound in osteoporosis and bone metabolism pathologies. Radiol Clin North Am 2010;48:577-588.
30. Diacinti D, Guglielmi G. Vertebral morphometry. Radiol Clin North Am 2010;48:561-575.
31. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385-397.
32. Hans DB, Kanis JA, Baim S, et al. FRAX(®) Position Development Conference Members. Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice. J Clin Densitom 2011 Jul-Sep;14(3):171-80.
33. McCloskey E, Kanis JA. FRAX updates 2012. Curr Opin Rheumatol 2012;24:554-560.
34. Reginster JY. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 2011;71:65-78.
35. Brandi ML. Sustained vertebral antifracture efficacy of oral anti-osteoporotic therapies in postmenopausal osteoporosis. Curr Med Res Opin 2010;26:2553-2563.
36. McClung M, Harris ST, Miller PD, et al. Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday. Am J Med 2012 Nov 20. [Epub ahead of print].
37. Hellstein JW, Adler RA, Edwards B, et al. American Dental Association Council on Scientific Affairs Expert Panel on Antiresorptive Agents. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2011 Nov;142(11):1243-51.
38. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19:257-271.
39. Painter SE, Kleerekoper M, Camacho PM. Secondary osteoporosis: a review of the recent evidence. Endocr Pract 2006 Jul-Aug;12(4):436-45. (Pubitemid 44717606)
40. Hudec SM, Camacho PM. Secondary Causes of Osteoporosis. Endocr Pract 2012:1-31.
41. Rizzoli R, Adachi JD, Cooper C, et al. Management of glucocorticoid- induced osteoporosis. Calcif Tissue Int 2012;91:225-243.
42. Bilezikian JP, Khan AA, Potts JT Jr. Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009;94:335-339.
43. Marcocci C, Cianferotti L, Cetani F. Bone disease in primary hyperparathyrodism. Ther Adv Musculoskelet Dis 2012;4:357-368.
44. Chauhan V, Ranganna KM, Chauhan N, et al. Bone disease in organ transplant patients: pathogenesis and management. Postgrad Med 2012;124:80-90.
45. Gatti D, Viapiana O, Idolazzi L, et al. Neridronic acid for the treatment of bone metabolic diseases. Expert Opin Drug Metab Toxicol 2009;5:1305-1311.